Stason Pharmaceuticals

Executive Summary

Stason Pharmaceuticals is a US-based private pharmaceutical company founded in 2003, headquartered in Irvine, California. The company focuses on small molecules and drug delivery, with core therapeutic areas in oncology, renal, and orphan indications. Beyond its own product development, Stason offers contract packaging, analytical testing, and CDMO services to drug-development companies, including clinical trial materials and commercial production of high potency products. In 2025, the company expanded its commercial lines to manufacture consumer supplement products, diversifying its revenue streams. Stason's dual business model—combining proprietary drug development with contract services—positions it as a versatile partner in the pharmaceutical ecosystem. Its recent entry into the supplement market suggests a strategic pivot to leverage manufacturing capabilities for over-the-counter products. While the company lacks publicly disclosed pipeline candidates or approved drugs, its CDMO services provide a steady revenue base and potential for partnerships. The company's long history since 2003 indicates operational stability, though growth will depend on securing new clients for its expanded supplement line and advancing any internal programs in oncology or orphan diseases.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of consumer supplement line expansion75% success
• Q4 2026New CDMO partnership with oncology biotech50% success
• TBDRegulatory filing for lead orphan drug candidate30% success